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Studies of the last decades have revealed the importance of angiogenesis for normal growth and for the pathogenesis of
numerous diseases. Much less studied is lymphangiogenesis, the growth of lymphatic vessels, which drain extravasated
fluid, proteins, and cells and transport them back to the venous circulation. Nonetheless, insufficient lymphangiogenesis
causes incapacitating lymphedema, while lymphatic growth around tumors may facilitate metastatic spread of malignant cells
that ultimately kill the patient.The recent discovery of the key lymphangiogenic factors VEGF-C and VEGF-D and their recep-
tor VEGFR-3 has allowed novel insights into how the lymphatic vessels and blood vessels coordinately grow and affect
human disease. In addition, these studies have opened novel diagnostic and therapeutic avenues for the treatment of lym-
phedema and metastasis. This overview highlights the recent insights and developments in the field of lymphatic vascular
research.
Lymphatic vessels in health and disease
When blood circulates through the vascular system, fluid and
proteins unavoidably leak out. A network of lymphatic vessels
collects the extravasated bloodless fluid from the tissues and
transfers it, as lymph, via the collecting lymphatic vessels and
thoracic duct back into the venous circulation. Lymphatic ves-
sels also serve an immune function by transporting white blood
cells and antigen-presenting cells which patrol the tissues to the
various lymphoid organs, where they elicit immune responses
(Figure 1). The superficial lymphatics in the skin and intestine,
which are in contact with foreign antigens, function as transport
routes for antigen-presenting Langerhans cells and other lym-
phoid cells. Unfortunately, malignant cells that escape from their
resident tumor can also traffic along the lymphatic tracts to the
lymph nodes and, via entry into the circulation, cause metastat-
ic spread to distant organs (Figure 1). In view of its important
functions, is not surprising that derailed growth or function of the
lymphatic system is implicated in numerous diseases, including
lymphedema, inflammation/infection, immune diseases, and
malignancy (reviewed in Karpanen and Alitalo, 2001; Pepper,
2001). Remarkably, however, even though lymphatic vessels
were already discovered as “milky veins” in 1627 by Gasparo
Asellius (Asellius, 1627), their study has remained relatively
neglected until recently. This has been partly due to the difficul-
ties in recognizing these vessels in tissues, due to a lack of spe-
cific markers. The recent identification of molecules that control
the growth of lymphatic vessels therefore has important medical
implications.
Are lymphatic and blood vessels alike?
The lymphatic vessels differ in many ways from the blood ves-
sels, but they also share many properties. Both vascular sys-
tems are lined by an endothelium and surrounded by a smooth
muscle framework, particularly around luminal valves in larger
lymphatics (Witte et al., 1997). Although both vessel types are
likely to share a common embryonic origin (see below), they
also display several distinct molecular markers (Table 1 lists
some lymphatic markers). Even certain factors that stimulate
blood vessel growth also enhance lymphatic growth (Kubo et
al., 2002). Unlike blood vessels, lymphatic vessels have a dis-
continuous or fenestrated basement membrane, lack tight
interendothelial junctions, and are therefore permeable to inter-
stitial fluid and cells (Leak, 1976). Through specialized anchor-
ing filaments (e.g., fine strands of elastic fibers connecting lym-
phatic endothelial cells with their surrounding pericellular matrix
[Gerli et al., 2000]), the lymphatic vessels stay open when the
tissue pressure rises. Compared to the blood vessels, lymphat-
ics are a low flow, low pressure system and much less coagula-
ble due to lack of platelets and erythrocytes. They also send out
fewer sprouts and are organized in a less complex network
(Witte et al., 1997). Identification of lymphatic vessels therefore
relies on the use of several markers (Table 1) and, ideally, on
functional assays demonstrating uptake of dyes (lymphangiog-
raphy) (Jain et al., 2002).
The genesis of lymphatic vessels in the embryo
Blood vessels initially arise via vasculogenesis, e.g., via the
assembly of differentiated endothelial precursors into a primitive
capillary network (Figure 2). Subsequently, the nascent vascu-
lar bed expands and remodels into a mature network, a process
termed angiogenesis (Carmeliet, 2000) (Figure 2). Lymphatic
vessels develop shortly after blood vessels and might share a
common origin with the latter. Around the turn of the century,
Sabin proposed that primitive lymph sacs originate by endothe-
lial cell budding from embryonic veins (Huntington and McLure,
1908; Sabin, 1902) (Figure 2). The peripheral lymphatic system
would then spread from these primary lymph sacs by sprouting
and assembly into lymphatic capillaries. Now, a century later,
genetic studies support a model whereby certain venous
endothelial cells become responsive to (as yet unknown) lym-
phatic-inducing signals, differentiate to the lymphatic lineage,
and send out lymphatic sprouts. Prox-1, a homeobox transcrip-
tion factor, plays a critical role in the initial trans-differentiation
and subsequent budding (Wigle and Oliver, 1999), while
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VEGFR-3, a receptor of the lymphangiogenic factor vascular
endothelial growth factor-C (VEGF-C; Joukov et al., 1996, see
below), is initially expressed in embryonic blood vessels, but
subsequently restricted to lymphatic vessels once they are
committed to this lineage and express additional lymphatic
markers (see Table 1) (Kaipainen et al., 1995). According to an
alternative model, the initial lymph sacs would arise in the mes-
enchyme from precursor cells (lymphangioblasts), independent
of the veins, and only later establish venous connections (the
equivalent of “vasculogenesis”; Figure 2).The existence of prim-
itive lymphangioblasts, which can be recruited by the develop-
ing lymphatic vessels, has been shown at least in the avian
species (Schneider et al., 1999). A combination of both mecha-
nisms is therefore likely to contribute to the formation of the lym-
phatic system.
Molecular regulation of lymphangiogenesis in disease
Blood vessels in the adult are normally quiescent and require
signals to grow (“angiogenic switch”). It is now widely accepted
that the switch is off when the effect of proangiogenic molecules
is balanced by that of antiangiogenic molecules, and is on when
the net balance is tipped in favor of angiogenesis (Carmeliet
and Jain, 2000; Hanahan and Folkman, 1996). Several mole-
cules have been implicated, but members of the VEGF family of
growth factors (VEGF, VEGF-B, -C, -D, and PlGF) and their
receptors (VEGFR-1, -2, and -3) play critical roles in mediating
angiogenic processes (Carmeliet, 2000; Carmeliet et al., 2001;
Dvorak, 2000; Ferrara, 2001; Karkkainen and Petrova, 2000). Of
those, activation of VEGFR-2 by VEGF provides crucial angio-
genic signals. Much less is known, however, about the signals
switching on lymphangiogenesis in pathological disorders.
Since lymphatic vessels arose from blood vessels, it is not sur-
prising that some of the prototype angiogenic mechanisms are
also employed in lymphangiogenesis. This is the case for
VEGF-C and VEGF-D, which interact with VEGFR-3 in lymphat-
ic endothelial cells (Joukov et al., 1997; Kaipainen et al., 1995;
Achen et al., 1998). VEGF-C and VEGFR-3 are usually coex-
pressed at sites where lymphatic vessels sprout, in the embryo
(Dumont et al., 1998; Kukk et al., 1996), and in disease (see
below). VEGF-C induces growth, migration, and survival of pri-
mary lymphatic endothelial cells (Makinen et al., 2001b), stimu-
lates lymphatic sprouting in the chorioallantoic membrane (Oh
et al., 1997), and, when overexpressed in transgenic mice, lym-
phatic vessel hyperplasia (Jeltsch et al., 1997). Signaling via
VEGFR-3 alone was sufficient for the lymphangiogenic signals,
since VEGF-CC156S, which only activates VEGFR-3 but not
Figure 1. Scheme illustrating the relationship between blood vascular and lymphatic system in normal health and in cancer
A: In a healthy individual, lymphatics drain extravasated fluid, proteins, and cells to the lymph nodes and, via the thoracic duct, to the venous circulation.
Immune cells such as antigen-presenting cells, patrolling through the body for foreign antigens, traffic to the lymph nodes, where they elicit an immune
response. Lymphedema develops when lymphatic drainage is insufficient as a result of primary hypoplasia, surgical resection, radiation, infection (such as
filariasis), etc. B: In cancer, as a result of lymphangiogenesis around and possibly also within (controversial) the primary tumor (1), dislodged tumor cells drain
to the lymph nodes, which represents a poor prognosis (2). Tumor cells then traffic to the vascular circulation, through which they metastasize to distant
organs and kill the patient (3). Since tumors are highly angiogenic, tumor cells may also metastasize via an hematogeneous route to distant organs (4),
which may explain why inhibition of lymphangiogenesis blocks lymph node but not lung metastasis in an experimental tumor model (see text).
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VEGFR-2, induced a similar phenotype (Veikkola et al., 2001).
VEGF-D is also lymphangiogenic when overexpressed in skin
keratinocytes (Veikkola et al., 2001). Little is known about the
expression of VEGF-D in physiological conditions, but it is
expressed in tumors (Achen et al., 2001) (see below). It remains
to be determined to what extent VEGF, via binding to VEGFR-2
on lymphatic endothelial cells (Makinen et al., 2001b), directly
stimulates lymphangiogenesis or stimulates it indirectly by
inducing leakage and edema or other lymphangiogenic signals.
Lymphangiogenesis appears to often accompany angio-
genesis (Figure 3). This is understandable since nascent blood
vessels are leaky, and lack of accompanying lymphatic growth
would result in increasing tissue edema. For instance, during
wound healing, VEGFR-3 positive lymphatic vessels sprout
from preexisting lymphatics into the granulation tissue in paral-
lel with angiogenesis (Clark and Clark, 1932; Oden, 1960;
Paavonen et al., 2000). When there is an imbalance in the
growth of both vascular systems (as can, for instance, occur in
tumors), the interstitial pressure may rise (see below). The
molecular properties of VEGF-C and VEGF-D link angiogenesis
with lymphangiogenesis, as they stimulate both processes.
Indeed, VEGF-C and VEGF-D are synthesized as prepropro-
teins, and proteolytic processing enhances their receptor bind-
ing to VEGFR-3 (predominantly a lymphangiogenic receptor),
while only the fully processed forms bind to and activate
VEGFR-2 (primarily an angiogenic receptor) (Joukov et al.,
1996, 1997; Achen et al., 1998).Thus, both angiogenic and lym-
phangiogenic signals can be coordinately generated from a sin-
gle molecule, depending on the degree of processing and the
relative expression of the receptors. This may explain why
VEGFR-3 deficient embryos succumb due to vascular defects
(Dumont et al., 1998), why VEGF-C affects early vascular devel-
opment in the chorioallantoic membrane before the emergence
of the lymphatics, and why angiogenesis is enhanced in the
ischemic limb by VEGF-C, and in the cornea by VEGF-C and
VEGF-D (Cao et al., 1998; Marconcini et al., 1999;
Witzenbichler et al., 1998).
Considering the complexity of the molecular regulation of
angiogenesis, regulation of lymphangiogenesis is likely to be as
complex. Initial insights into the role of additional lymphangio-
genic signals have been recently derived from gene targeting
studies. For instance, loss of angiopoietin-2, another vascular-
specific growth factor that binds the Tie-2 receptor tyrosine
kinase, results in abnormal lymphatic patterning and function
(N. Gale, G. Yancopoulos, et al., submitted). In addition, mice
with deficient DNA binding of Net, a member of the Ets-domain
transcription factor that is coexpressed with VEGFR-3 in lym-
phatic vessels, succumb neonatally of insufficient lymph
drainage (Ayadi et al., 2001). Furthermore, integrin α9β1 seems
required for proper lymphatic development, as α9 deficient
neonates succumb due to similar lymph drainage problems
(Huang et al., 2000). This may relate to a cooperation between
α9β1 and VEGFR-3 signaling (Wang et al., 2001). A major
advance in the field has been the discovery of additional lym-
phatic markers (Table 1), and a challenge for the future is now to
unravel their function in vivo.
Lymphedema, a failure of lymph transport
An imbalance between lymph formation and absorption into
lymphatic vessels results in edema. Lymphedema due to
impaired lymphatic drainage can be caused by inflammatory or
neoplastic obstruction of the lymphatic vessels (Figure 3). For
instance, ascites fluid may accumulate due to lymphatic
obstruction in peritoneal carcinomatosis, or edema of the arm
may follow surgery or radiotherapy for breast cancer, or in non-
healing wounds. Lymphatic filariasis, the second leading cause
of permanent and long-term disability worldwide, is a parasitic
infection in the lymphatic vessels, which leads to abnormal
transport function, massive edema, and deformation of the
limbs (Witte et al., 1997). Primary lymphedema due to a trans-
port failure of the cutaneous lymphatic vessels gradually results
in thickening of the skin, accumulation of adipose tissue, and
dermal fibrosis of the affected area. Congenital lymphedema
(Milroy’s disease) is linked to the VEGFR-3 gene with autoso-
mal dominant inheritance (Ferrell et al., 1998; Witte et al.,
1998). This mutation reduces the VEGFR-3 tyrosine kinase
activity with subsequent failure in transducing VEGF-C/VEGF-D
signals (Karkkainen et al., 2000). Experimentally, transgenic
overexpression of a soluble VEGFR-3 (a “VEGF-C/D trap”) in
the skin also causes lymphedema (Makinen et al., 2001a).
Besides VEGFR-3, FOXC2 gene mutations cause primary lym-
phedema (Fang et al., 2000), and other genes are likely
involved in this disease. Identification of genetic markers and
high-risk members of lymphedema families would facilitate the
identification and management of lymphedema.
Lymphangiomas and Kaposi’s sarcoma
Derailed growth of VEGFR-3/podoplanin-positive lymphatic
vessels results in lymphangioma formation with secondary lym-
phedema due to impaired lymph fluid drainage.
Lymphangiogomas affect most organs, although they are most
commonly found in the soft tissues of the head, neck, and axilla,
Table 1. Lymphatic markers, their expression pattern and putative function
Marker Comments
VEGFR-3 Receptor of VEGF-C and VEGF-D in lymphatic endothelium (Jussila et al., 1998; Kaipainen et al., 1995); also present in a subset of 
blood vessels and reactivated in angiogenic vessels during pathological conditions (Partanen et al., 2000; Valtola et al., 1999)
Podoplanin Glomerular podocyte membrane mucoprotein, coexpressed with VEGFR-3 in small lymphatic vessels, but also in vascular tumors
and in osteoblasts, kidney podocytes and lung alveolar type I cells (Breiteneder-Geleff et al., 1999)
Prox-1 Homeobox transcription factor involved in the growth and differentiation of lymphatic vessels during development; also
expressed in the lens, heart, liver, pancreas, and nervous system. Prox-1-deficient neonates die of defective lymphatic sprouting
and differentiation (Wigle and Oliver, 1999)
LYVE-1 Lymphatic Vessel Endothelial HA-receptor-1 (homolog of CD44), involved in transport of hyaluronan by lymphatic endothelial
cells. Also present in normal kidney, pancreas, adrenal, and thyroid epithelia and in hepatic blood sinusoidal endothelial
cells (Carreira et al., 2001; Banerji et al., 1999)
Nrp-2 Neuropilin-2, a receptor for VEGF on venous endothelium and neurorepellant semaphorins on neural cells, is also a coreceptor
of VEGF-C in lymphatic vessels (Karkkainen et al., 2001)
Figure 2. Scheme illustrating the formation of
vascular blood and lymphatic vessels
Upper panels: endothelial precursors (Angio-
blasts) differentiate to a primitive capillary net-
work (Vasculogenesis), which subsequently
remodels and expands to a mature vascular
network (Angiogenesis) of arteries (red) and
veins (blue). Lower panels: during embryonic
development, venous endothelial cells respond
to putative lymphangiogenic signals and differ-
entiate to lymphatic endothelial cells (green)
(Lymphatic commitment). Lymphatic vessels
further sprout, expand, and remodel and estab-
lish an open-ended vessel system that connects
to the venous circulation (Lymphangiogen-
esis). Alternatively, lymphatic angioblasts may
differentiate to lymphatic endothelium and
form new vessels. Some essential molecules
defining the (lymph)-angiogenic switch being
on or off are indicated. Abbreviations: VEGFR,
VEGF receptors; Ang, angiopoietin; FGF, fibrob-
last growth factor; HGF, hepatocyte growth
factor; MCP-1, monocyte chemoattractant
protein-1; MMP, matrix metalloproteinase; HIF,
hypoxia inducible factor. Synthetic inhibitors
such as VEGF receptor tyrosine kinase inhibitors
and blocking VEGFR-3 antibodies can also
block lymphangiogenesis, etc. (see text).
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where they consist of a benign multicystic mass of networks of
dilated lymphatic channels. Findings that spindle cells and cells
lining the irregular vascular spaces in Kaposi’s sarcoma in AIDS
patients are positive for VEGFR-3 and podoplanin suggest that
these cells could be of lymphatic endothelial origin (Jussila et
al., 1998; Skobe et al., 1999; Weninger et al., 1999).
Blood vessels and lymphatic vessels in tumors
Like in normal tissues, both vascular and lymphatic vessels are
present in malignant tissues, but some remarkable differences
with normal vessels have been observed. Unraveling how
angiogenesis and lymphangiogenesis are derailed in tumors is
of major importance for understanding tumor biology and
designing future cancer preventive measures. Since both vas-
cular systems probably crosstalk to each other and share com-
mon signals, their structural and functional aspects are com-
pared. Tumor vascular vessels are highly disorganized, tortu-
ous, and dilated with uneven diameter, excessive branching,
shunts, and incomplete or absent muscular coverage
(Carmeliet and Jain, 2000). Their walls have numerous “open-
ings,” widened interendothelial junctions, and a discontinuous or
absent basement membrane. In addition, the endothelial cells
are abnormal in shape, growing on top of each other and pro-
jecting into the lumen. Consequently, tumor vessels are leaky
and blood flow is chaotic and variable, all contributing to
increased interstitial tumor pressure and impairing delivery of
therapeutic agents in tumors (Jain and Carmeliet, 2001).
Tumor lymphatic vessels have been less studied, in part
due to lack of appropriate molecular markers. In addition,
because of technical challenges involved in performing func-
tional lymphangiography, a highly debated and unresolved
question nowadays is whether there are functional lymphatic
vessels inside tumors (see below) (Jain and Fenton, 2002).
Indeed, depending on the molecular markers used to label
putative lymphatic vessels and the tumor model or type used to
study tumor lymphangiogenesis, intratumoral lymphatic vessels
were documented in tumor xenografts overexpressing VEGF-C
or VEGF-D (Karpanen et al., 2001; Skobe et al., 2001; Stacker
et al., 2001) or in head and neck squamous cell carcinomas
(Jackson et al., 2001). However, no such intratumoral lymphatic
vessels were detectable in other tumors, such as in invasive
breast cancer (Jackson et al., 2001), or in VEGF-C transgenic
mouse tumors (Mandriota et al., 2001). This discrepancy may
be at least partially explained by the trapping of vessels in
between the rapidly growing tumor foci in the xenografts. An
outstanding, yet critical, question is whether these intratumoral
VEGFR-3/LYVE-1 positive vessels are functional lymphatics.
Indeed, lymphangiography by intravital microscopy after injec-
tion of dyes in experimental animal models of implanted and
spontaneously arising tumors reveals that lymphatic vessels in
the periphery of the tumors are enlarged and perfused, but
compressed and nonfunctional in the inside of the tumor (Jain
and Fenton, 2002). One explanation may be that neoplastic
cells grown in a confined space generate mechanical stress,
which compresses the newly formed lymphatic channels inside
the tumor, while at the periphery, excess VEGF-C causes lym-
phatics to enlarge.These enlarged lymphatics may collect inter-
stitial fluid and metastatic cancer cells “oozing” from the tumor
surface, and thus facilitate lymphatic metastasis. Absence of
functional lymphatics within tumors may contribute to interstitial
hypertension and interfere with the delivery of therapeutic
agents (Carmeliet and Jain, 2000).
Metastasis via lymphatic vessels
In most instances, metastatic spreading of tumors to distant
organs—not the local growth of the primary tumor—kills the
patient.Tumor metastasis involves a series of complex process-
es that include the detachment of tumor cells from the primary
tumor mass, microinvasion into stromal tissues, intravasation
into the lymphatic or blood vessels, and extravasation and
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growth in secondary sites. Tumor cells spread via the lymphatic
system to regional lymph nodes and, because the large lym-
phatic vessels reenter into the blood vascular system, to distant
organs (Figure 1). Sentinel lymphnodectomy is used in daily
hospital practice to diagnose metastasis of primary tumor cells
to regional lymph nodes and to evaluate the prognosis and
appropriate treatment schedules. Even though most dissemi-
nated tumor cells have a limited life span and only a few develop
into clinically detectable metastases, identification of those
occult tumor cells and prevention of their growth and spread
would be of great clinical significance. Few data are available on
the influence of lymphatic microvessel density on survival in
cancer, because until recently there was no reliable immunohis-
tological marker for the lymphatic endothelium. In ovarian can-
cer, lymphatic vessel density was not correlated to the progres-
sion of the disease (Birner et al., 2000), while in cervical cancer,
an increased amount of lymphatic vessels even appeared to be
associated with a favorable prognosis (Birner et al., 2001). It is
likely that human tumors demonstrate heterogeneity with
regard to the presence or absence of intratumoral lymphatics.
Considering the lack of specificity of currently used markers to
identify lymphatic vessels, multiple markers should be used in
elucidating any correlation between lymphatic vessel density
and tumor growth, metastases, and prognosis, at least until the
specificity of these markers in lymphatic vessels during tumor
progression and metastases has been clarified.
VEGF-C and VEGF-D in experimental tumor lymphangio-
genesis
Recent experimental models have highlighted the role of VEGF-
C and VEGF-D in tumor biology. Transgenic mice overexpress-
ing VEGF-C in β cells of the endocrine pancreas developed
extensive lymphangiogenesis around the endocrine islets of
Langerhans (Mandriota et al., 2001). When tumors were
induced in these VEGF-C overexpressing islets by intercrossing
with mice expressing the SV40 T-antigen oncogene in the β
cells, metastatic tumor cell aggregates of β cell origin were
observed in the surrounding lymphatic vessels.These mice also
frequently developed metastases in the lymph nodes, which
drain the pancreas, whereas tumors in mice lacking the VEGF-
Figure 3. Scheme illustrating the interrelationship between angiogenesis and lymphangiogenesis
A: In normal tissues, lymphatic vessels balance blood vessels by draining extravasated fluid, macromolecules, and white blood cells so that the interstitial
pressure does not increase due to edema. B: In wounds, lymphangiogenesis increases coincidently with angiogenesis to drain extravasated fluid from leaky
neovessels, thereby preventing excessive lymphedema. C: When lymphatic vessels are damaged (radiation therapy) or are hypoplastic, obstructed (due
to infection and inflammation), or removed (surgery), lymph drainage is insufficient, resulting in lymphedema and increased interstitial tissue pressure. 
D: Therapeutic lymphangiogenesis with VEGF-C (or perhaps VEGF-D) improves tissue fluid drainage by stimulating the growth of new lymphatic vessels (1).
Whether collateral lymphatic vessels can also be stimulated to grow (as in blood vascular vessels) remains to be determined (2). E: In tumors, lymphangio-
genesis and angiogenesis are not (necessarily) balanced. Blood vessels grow excessively inside tumors but, due to their grossly abnormal structure and
function, excessive fluid leaks out and increases the interstitial tumor pressure, thereby compressing intratumor lymphatic vessels. Lymphatic vessels around
tumors become hyperplastic and facilitate metastatic spreading of tumor cells to the lymph nodes. Tumor cells can, however, also metastasize via an
hematogeneous route, which is facilitated by tumor angiogenesis.
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C transgene never metastasized, nor were tumor cells observed
inside the lymphatic vessels (Mandriota et al., 2001). VEGF-C
overexpression by the tumors did not significantly alter tumor
volume, transition from adenoma to carcinoma, or tumor angio-
genesis, but, intriguingly, tumor incidence was increased—for
as yet unknown reasons. Ectopic expression of VEGF-C in
human breast cancer cells induced lymphangiogenesis in and
around the orthotopically implanted tumors (Karpanen et al.,
2001; Skobe et al., 2001) and enhanced tumor growth and
spreading to regional lymph nodes, and, notably, the degree of
tumor lymphangiogenesis correlated with lymph node metas-
tases (Karpanen et al., 2001; Skobe et al., 2001; Mattila et al.,
2002).
VEGF-D also promotes the metastatic spread of tumor cells
via the lymphatics (Stacker et al., 2001). In addition to lymphan-
giogenesis and increased metastases, tumors secreting VEGF-
D had an increased growth rate and tumor angiogenesis.
Growth of the tumor, angiogenesis, and formation of metas-
tases were inhibited by anti-VEGF-D antibodies. The differ-
ences between the tumor angiogenic properties of VEGF-C and
VEGF-D may be due to differences in their proteolytic process-
ing in different tumors or the variable expression of VEGFR-2
and VEGFR-3 on blood vascular and lymphatic endothelia. In
particular, in the above case, enhanced tumor angiogenesis by
VEGF-D was probably attributable to its increased proteolytic
processing, resulting in a VEGF-D form with an increased affin-
ity to VEGFR-2 (Stacker et al., 2001). Consistent with this
model, the vascular effects of VEGF-C in experimental tumors
were reduced by anti-VEGFR-2 antibodies (Kadambi et al.,
2001). On the basis of these observations, tumor vessel forma-
tion can be dissected into pathways that preferentially activate
angiogenesis (driven by VEGFR-2) or lymphangiogenesis (dri-
ven by VEGFR-3), although there is evidence that the receptors
share overlapping expression patterns.
In theory, VEGF-C and VEGF-D could facilitate metastasis
by increasing the surface area of tumor cells in contact with the
lymphatic endothelium, by increasing vascular permeability,
and/or by changing the adhesive properties or
cytokine/chemokine expression of the lymphatic endothelium.
These factors could also alter the tumor interstitial fluid pres-
sure, which might determine tumor cell seeding, especially as
recent studies revealed that a proportion of the lumen of tumor
blood vessels themselves consists of tumor cells (Chang et al.,
2000). Other molecules are likely to contribute to lymphatic
metastasis. Indeed, attraction of CCR7-positive tumor cells to
SLC-expressing lymphatic endothelium enhanced lymph node
metastasis (Muller et al., 2001).
VEGF-C and VEGF-D in human tumors
It is still unknown whether VEGF-C or VEGF-D expression also
promotes lymphangiogenesis in human tumors, and, if so,
whether this increases the rate of metastasis to the lymph
nodes. VEGF-C expression is detectable in about half of human
cancers analyzed (Salven et al., 1998). A number of reports
have described a correlation between VEGF-C expression in
human tumors and the formation of metastases in regional
lymph nodes. So far, VEGF-C levels in primary tumors have
been shown to correlate significantly with lymph node metas-
tases in thyroid, prostate, gastric, colorectal, lung, and
esophageal carcinomas (reviewed in Karpanen and Alitalo,
2001; Pepper, 2001). Less is known about the expression of
VEGF-D in human tumors: it is upregulated in human
melanoma cells and in vessels adjacent to immunopositive
tumor cells, but not in vessels distant from the tumors (Achen et
al., 2001), suggesting that VEGF-D binds to the endothelial
cells of nearby vessels and contributes in a paracrine manner to
the regulation of tumor angiogenesis.
Lymphatic metastasis versus distant organ metastasis
Overexpression of VEGF-C in orthotopic breast tumor cells
enhanced tumor metastasis to regional lymph nodes and the
lungs (Skobe et al., 2001). However, the presence of a metasta-
sis in a lymph node does not necessary mean that the tumor
cells have been arrived via the lymphatic vessels. Intralymphatic
tumor cells may pass directly into the blood vascular system
through venolymphatic communications, which have been
observed in certain organs. An increase in circulating tumor cells
in the peripheral blood, resulting from enhanced tumor angio-
genesis, could also facilitate lymph node metastases. In a recent
study, a highly metastatic human lung cancer cell line LNM35
and its parental line N15 with low metastatic capacity were used
(He et al., 2002). LNM35 tumor cells, expressing the highest
amounts of VEGF-C, showed intratumoral lymphatic vessels and
metastases in the draining lymph nodes. Even though lymphan-
giogenesis and lymphatic metastasis were suppressed in
LNM35 tumors expressing a soluble form of VEGFR-3, tumors
still metastasized to the lungs, suggesting that LNM35 cells can
spread via other mechanisms and routes, for instance the blood
(Figure 1). These data demonstrate that blockage of VEGFR-3
signaling can suppress tumor lymphangiogenesis and lymphatic
metastasis, but not necessarily lung metastasis, indicating that
the mechanisms of lymphatic and lung metastasis may differ (He
et al., 2002). Thus, overexpression of VEGF-C and the associat-
ed de novo formation of lymphatic vessels are necessary, but not
sufficient, for the metastatic dissemination of tumor cells to the
lymph nodes. Factors in addition to VEGF-C are thus apparently
required for metastatic spread.
Antilymphangiogenic therapy
VEGF-C-induced tumor growth, lymphangiogenesis, and intra-
lymphatic tumor growth were inhibited by adenoviral expression
of the soluble VEGFR-3 receptor, which “traps” available VEGF-
C and VEGF-D (Karpanen et al., 2001) (Figure 3). Inhibition of
VEGFR-3 by neutralizing antibodies also suppressed tumor
growth by destabilizing large vessels in tumor xenografts in
mice (Kubo et al., 2000), without affecting the established blood
and lymphatic vasculature. Furthermore, lymphatic spread
induced by VEGF-D was blocked with an antibody specific for
VEGF-D (Stacker et al., 2001). In theory, anticancer drugs
specifically targeted to peritumoral lymphatic vessels might
inhibit lymphatic metastasis. However, caution is warranted,
since destruction of these vessels could further elevate the
already increased interstitial fluid pressure inside the tumors,
thereby further impairing the delivery of other anticancer drugs.
As VEGF-D expression can be upregulated by direct cell-cell
contacts, one can also speculate that an increased intratumoral
pressure could increase close contacts between the tumor cells
and lead to a compensatory increase of the lymphangiogenic
growth factor levels (Orlandini and Oliviero, 2001). Increased
intratumoral fluid pressure could also enhance the likelihood of
hematogeneous metastasis (Carmeliet and Jain, 2000; Stohrer
et al., 2000).
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Therapeutic lymphangiogenesis
At present, lymphedema is treated by manual lymphatic
drainage and by compressive garments. The discovery of spe-
cific genes involved in the regulation of lymphatic vessels and in
the pathology of lymphedema should make the design of more
targeted treatments for this disease possible. Indeed, subcuta-
neous adenoviral gene transfer of VEGF-C in normal mice
induced lymphangiogenesis (Enholm et al., 2001). More impor-
tantly, however, overexpression of VEGF-C in the skin of a
mouse model (Chy) of lymphedema (due to an inherited partial
loss of VEGFR-3 activity) also enhanced growth of functional
cutaneous lymphatic vessels (Karkkainen et al., 2001), sug-
gesting that VEGF-C/D gene therapy may be applicable to
human lymphedema (Figure 3). It remains to be determined
whether such therapy could also be used in nonhereditary,
regional forms of lymphedema resulting from trauma, surgery,
or lymphatic vessel destruction after filariasis. Future studies
will need to address the differences in the molecular “lymphan-
giogenic switch” between lymphatic vessels in the skin versus
the visceral organs or the larger connecting lymphatic vessels,
as those vessels are differently regulated by VEGFR-3 signals
(Karkkainen et al., 2001). In addition, it remains to be examined
whether lymphangiogenesis in adults is only mediated by
endothelial cell sprouting from or splitting of preexisting lym-
phatic or blood vessels or in situ differentiation of endothelial
cells—or, alternatively, whether new lymphatic vessel growth
can be stimulated by enhancing or recruitment and lymphatic
differentiation of endothelial precursor cells, as has been
described in other models (Schneider et al., 1999). The latter
would be attractive, as it would allow cell transplantation for
regeneration of damaged or insufficient lymphatic vessels.
Conclusion
The recent discovery of the key molecules VEGF-C and VEGF-
D and the isolation of lymphatic endothelial cells have allowed
studies of lymphangiogenesis at the molecular level. Similarities
between the regulation of blood and lymphatic vessels have
been observed, and these two vessel systems appear to work
in a tightly regulated manner. Thus far, results on therapeutic
lymphangiogenesis with VEGF-C for lymphedema and inhibi-
tion of metastatic spread of tumor cells via the lymphatic vascu-
lature by blocking VEGFR-3 signaling have been most encour-
aging. Future clinical trials will show the therapeutic potential of
these molecules in man.
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